Laird Norton Wetherby Wealth Management’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $2.49M | Buy |
97,858
+10,917
| +13% | +$269K | 0.1% | 195 |
|
|
2025
Q2 | $2.11M | Buy |
+86,941
| New | +$2.03M | 0.09% | 213 |
|
|
2024
Q4 | $2.21M | Sell |
83,179
-35,112
| -30% | -$952K | 0.11% | 187 |
|
|
2024
Q3 | $3.42M | Sell |
118,291
-5,450
| -4% | -$159K | 0.16% | 113 |
|
|
2024
Q2 | $3.46M | Buy |
123,741
+8,483
| +7% | +$234K | 0.16% | 109 |
|
|
2024
Q1 | $3.2M | Sell |
115,258
-20,351
| -15% | -$565K | 0.15% | 122 |
|
|
2023
Q4 | $3.9M | Sell |
135,609
-7,828
| -5% | -$237K | 0.2% | 89 |
|
|
2023
Q3 | $4.76M | Sell |
143,437
-12,125
| -8% | -$429K | 0.27% | 68 |
|
|
2023
Q2 | $5.71M | Buy |
155,562
+9,084
| +6% | +$354K | 0.31% | 55 |
|
|
2023
Q1 | $5.98M | Sell |
146,478
-8,335
| -5% | -$360K | 0.35% | 50 |
|
|
2022
Q4 | $7.93M | Buy |
154,813
+7,180
| +5% | +$344K | 0.51% | 26 |
|
|
2022
Q3 | $6.46M | Sell |
147,633
-1,179
| -0.8% | -$57.3K | 0.46% | 34 |
|
|
2022
Q2 | $7.8M | Buy |
148,812
+4,272
| +3% | +$218K | 0.53% | 28 |
|
|
2022
Q1 | $7.48M | Buy |
144,540
+4,053
| +3% | +$210K | 0.43% | 36 |
|
|
2021
Q4 | $8.3M | Buy |
140,487
+6,711
| +5% | +$333K | 0.47% | 33 |
|
|
2021
Q3 | $5.75M | Buy |
133,776
+603
| +0.5% | +$26.7K | 0.36% | 45 |
|
|
2021
Q2 | $5.21M | Buy |
133,173
+7,693
| +6% | +$299K | 0.32% | 55 |
|
|
2021
Q1 | $4.55M | Sell |
125,480
-13,361
| -10% | -$474K | 0.35% | 50 |
|
|
2020
Q4 | $5.11M | Buy |
138,841
+6,703
| +5% | +$246K | 0.35% | 50 |
|
|
2020
Q3 | $4.6M | Sell |
132,138
-3,280
| -2% | -$115K | 0.41% | 44 |
|
|
2020
Q2 | $4.2M | Buy |
135,418
+8,887
| +7% | +$302K | 0.4% | 42 |
|
|
2020
Q1 | $3.92M | Sell |
126,531
-9,182
| -7% | -$313K | 0.44% | 41 |
|
|
2019
Q4 | $5.04M | Buy |
135,713
+512
| +0.4% | +$18.2K | 0.5% | 35 |
|
|
2019
Q3 | $4.61M | Sell |
135,201
-15,734
| -10% | -$572K | 0.48% | 36 |
|
|
2019
Q2 | $6.2M | Buy |
150,935
+4,926
| +3% | +$196K | 0.68% | 23 |
|
|
2019
Q1 | $5.88M | Sell |
146,009
-138
| -0.1% | -$5.53K | 0.73% | 20 |
|
|
2018
Q4 | $6.05M | Buy |
146,147
+1,780
| +1% | +$73.9K | 0.86% | 16 |
|
|
2018
Q3 | $6.04M | Buy |
144,367
+2,093
| +1% | +$80.6K | 0.75% | 21 |
|
|
2018
Q2 | $4.9M | Buy |
142,274
+763
| +0.5% | +$26.1K | 0.66% | 23 |
|
|
2018
Q1 | $4.76M | Sell |
141,511
-956
| -0.7% | -$32.9K | 0.66% | 23 |
|
|
2017
Q4 | $4.89M | Buy |
142,467
+1,175
| +0.8% | +$40.1K | 0.68% | 20 |
|
|
2017
Q3 | $4.79M | Sell |
141,292
-31
| -0% | -$996 | 0.71% | 20 |
|
|
2017
Q2 | $4.5M | Buy |
141,323
+7,214
| +5% | +$228K | 0.77% | 18 |
|
|
2017
Q1 | $4.35M | Sell |
134,109
-7,388
| -5% | -$233K | 0.78% | 20 |
|
|
2016
Q4 | $4.36M | Buy |
141,497
+1,497
| +1% | +$45.7K | 0.85% | 18 |
|
|
2016
Q3 | $4.5M | Buy |
140,000
+3,492
| +3% | +$117K | 0.91% | 19 |
|
|
2016
Q2 | $4.56M | Buy |
136,508
+3,781
| +3% | +$121K | 1.01% | 15 |
|
|
2016
Q1 | $3.73M | Buy |
132,727
+5,397
| +4% | +$154K | 0.88% | 18 |
|
|
2015
Q4 | $3.9M | Sell |
127,330
-2,223
| -2% | -$69.9K | 0.94% | 17 |
|
|
2015
Q3 | $3.86M | Buy |
129,553
+1,264
| +1% | +$40.5K | 0.99% | 17 |
|
|
2015
Q2 | $4.08M | Buy |
128,289
+4,596
| +4% | +$150K | 0.98% | 16 |
|
|
2015
Q1 | $4.08M | Buy |
123,693
+3,847
| +3% | +$122K | 0.99% | 15 |
|
|
2014
Q4 | $3.54M | Buy |
119,846
+573
| +0.5% | +$16.4K | 0.89% | 18 |
|
|
2014
Q3 | $3.35M | Buy |
119,273
+3,549
| +3% | +$99.6K | 0.93% | 18 |
|
|
2014
Q2 | $3.26M | Sell |
115,724
-4,841
| -4% | -$138K | 0.92% | 19 |
|
|
2014
Q1 | $3.67M | Buy |
120,565
+184
| +0.2% | +$5.49K | 1.05% | 16 |
|
|
2013
Q4 | $3.5M | Sell |
120,381
-355
| -0.3% | -$10.3K | 1% | 17 |
|
|
2013
Q3 | $3.29M | Buy |
120,736
+516
| +0.4% | +$14K | 1.03% | 18 |
|
|
2013
Q2 | $3.19M | Buy |
+120,220
| New | +$3.32M | 1.11% | 17 |
|
Other funds holding PFE
Laird Norton Wetherby Wealth Management's PFE Position: Q3 2025 in Review
Laird Norton Wetherby Wealth Management increased its Pfizer (PFE) stake by 13% in Q3 2025, buying an estimated $269K and bringing the position to 97,858 shares worth $2.49M. The position accounts for 0.1% of the portfolio, ranked #195.
Laird Norton Wetherby Wealth Management first reported a position in PFE in Q2 2013 and has held it in 49 quarters since. The position peaked at $8.3M in Q4 2021. 2,811 funds tracked by Wall St. Rank hold PFE as of Q3 2025.
- Laird Norton Wetherby Wealth Management held 97,858 shares of Pfizer worth $2.49M as of Q3 2025.
- Laird Norton Wetherby Wealth Management bought 10,917 Pfizer shares in Q3 2025, an estimated $269K.
- Pfizer made up 0.1% of Laird Norton Wetherby Wealth Management's portfolio in Q3 2025, its #195 holding.
- Laird Norton Wetherby Wealth Management first reported a position in Pfizer in Q2 2013 and has held it in 49 quarters since.
- Laird Norton Wetherby Wealth Management's Pfizer position peaked at $8.3M in Q4 2021.
- 2,811 funds tracked by Wall St. Rank held Pfizer as of Q3 2025.
Based on Laird Norton Wetherby Wealth Management's 13F filing for Q3 2025, filed 14 Nov 2025.